In 2024 we celebrated 50 years since Shirley Nolan founded Anthony Nolan.
This milestone year saw us prepare to open our Cell Collection Centre, launch exciting new research projects, and explore innovative approaches to strengthening partnerships and collaborations to tackle inequities in accessing lifesaving treatments.
Our Impact Report highlights why these initiatives matter for patients, and how they will help us save lives of more patients and support families in the years ahead.
An introduction to our FY24/25 Impact report
Our year in numbers
Our patients
1,573 patients were given another chance to live.
761 patient grants were provided to support patients and families, totalling £188,000.
Our register
33,562 people were recruited to our register.
923,512 potential stem cell donors are now standing by to save lives on our register.
Our supporters
£9,169,000 was raised and donated by our dedicated supporters and partners
1,099 people gave their time to volunteer with us.
Our operations
1,803 cell donations for transplants were facilitated by Anthony Nolan for all patients (UK and international).
2,619 searches for unique patients in the UK were carried out by our Search and Selection Team.
Aim 1: Survival
To give every transplant patient the best chance – and quality – of life
In 2024 Anthony Nolan launched the SEQoL study, which stands for Scaled collection of socioEconomic and Quality of Life data from patients undergoing stem cell transplant. The project is the UK’s largest study aiming to understand the impact of a stem cell transplant on quality of life, and how this may be influenced by socioeconomic factors like education, income and housing.
Aim 2: Equity
To ensure all patients have the best access to, experience of and outcome from, treatment.
We have since established a cost-of-living working group with partner charities Macmillan and Young Lives v Cancer, with one of our first actions being to collate our evidence. We also took part in the joint Safe Sick Pay Campaign, led by the Centre for Progressive Change and Young Lives v Cancer.
Aim 3: Progress
To explore and embrace new cell therapies and make them available for patients more quickly.
Cell Therapy & Laboratory Services powered by Anthony Nolan is currently supporting academia, biotech, and pharmaceutical partners by supplying cellular starting material including leukopaks, mobilised leukopaks and cord derived products such as cord blood and tissue, placenta and amnion.
Find out more about the work we are undertaking in this aim on page 25.
Strengthening our foundations
We’re continuing to build on our strong foundations and proud history to achieve our ambitious goals. We’re using what we know, what we have and what drives us to continually move forward until the end of our strategy in 2028.
- Our patients
- Our people and culture
- Our diversity and inclusivity
- Our technology and data
- Out resilience and business model
All thanks to you!
Our achievements have only been made possible because of incredible dedication and generosity of our volunteers, donors, partners, funders, supporters, families and organisations that work with us.
Thank you for believing in our vision and for your continued commitment. Your support has been invaluable.